Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Female vs. Male Outcomes, Empower CAD
Join us in Las Vegas for VIVA 2022 as we crack into late breaking data supporting IVL’s consistency in calcium modification in real-world PAD. The late breaker, presented by Dr. Ehrin Armstrong, features the final 1,373 patient cohort datafrom the Disrupt PAD III Observational Study. Following the data release, an esteemed panel will discuss IVL’s consistent outcomes from both real-world AND randomized studies. Don’t roll the dice with calcium modification and join us at VIVA2022!
Despite often being more challenging to treat, female PCI patients are under-represented in published data, with no dedicated prospective studies performed on this population. To address this unmet need, Shockwave is launching EMPOWER CAD, the first prospective, female-only study of coronary interventions.
Attending TCT in Boston in a few weeks? Want to get "wicked smart" about treating coronary calcium? Shockwave has a lot in store for you:
Recognizing Shockwave’s commitment to drive value through clinical excellence and commitment to lower costs, Shockwave was announced a winner of the Supplier Horizon Award from Premier Inc., a leading healthcare improvement and technology company that unites an alliance of more than 4,400 U.S. hospitals and health systems and approximately 225,000 other providers. We're thrilled to be honored by Premier Inc. as a Supplier Horizon winner at the Breakthroughs Conference 2022 as it represents the support provided to Premier members of “exceptional customer service and engagement.”
Shockwave received this award for being a preferred supplier in the healthcare industry and demonstrating “unwavering commitment to delivering top value products and services designed to continually improve patient care.” This award, “recognizes suppliers - with less than three years of Premier tenure in a specific service line - that consistently support our members at the highest levels of partnership, customer service, value creation, clinical excellence, and commitment to lower costs.” Shockwave supports Premier members by offering valuable products and services that help to lower supply chain costs and improve operating efficiencies,” said David A. Hargraves, Senior Vice President, Supply Chain, Premier, “We’re honored to recognize them as a Horizon Award recipient.”
The full list of Premier’s 2022 Supplier Horizon Award winners can be found here.
We had an amazing time seeing you all in person at conferences this past quarter. We accomplished a great deal these past three months—from sharing the randomized Disrupt PAD III Study results at SCAI 2022 to launching Shockwave M5+ across the globe. JSCAI also published two articles discussing peripheral IVL for treatment of calcified common femoral artery disease, and the mid-term outcomes from the randomized Disrupt PAD III Trial. Check out the latest in the PulsePoint newsletter!
At Shockwave, we are committed to doing everything we can to narrow the PCI gender inequality gap starting with clinical evidence presented at SCAI 2022 where Coronary IVL demonstrated sustained long term clinical outcomes and excellent safety in both women and men suggesting first line use of Coronary IVL for plaque modification in female patients with calcified lesions.